Drug Trial Radar · NCT06733519
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis
Last checked: Nov 20, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Mar 1, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- Tharimmune IncIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study of TH104 in primary biliary cholangitis (PBC) participants with moderate to severe pruritus.
Conditions
- Pruritus
- Primary Biliary Cholangitis
Interventions
NalmefeneDrug
Th-104 Nalmefene Mucoadhesive Buccal strip
PlaceboDrug
Matching placebo to TH-104
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary objective is to investigate the safety and tolerability of repeat doses of TH104Time frame: 42 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.